AU2001296521A1 - Use of lymphangiogenic agents to treat lymphatic disorders - Google Patents

Use of lymphangiogenic agents to treat lymphatic disorders

Info

Publication number
AU2001296521A1
AU2001296521A1 AU2001296521A AU9652101A AU2001296521A1 AU 2001296521 A1 AU2001296521 A1 AU 2001296521A1 AU 2001296521 A AU2001296521 A AU 2001296521A AU 9652101 A AU9652101 A AU 9652101A AU 2001296521 A1 AU2001296521 A1 AU 2001296521A1
Authority
AU
Australia
Prior art keywords
lymphatic disorders
lymphangiogenic agents
treat lymphatic
treat
lymphangiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296521A
Inventor
Edwin C. Gravereaux
Jeffrey M. Isner
Silver Marcy
Young-Sup Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Elizabeths Medical Center of Boston Inc
Original Assignee
ST ELIZABETH S MEDICAL CT OF B
St Elizabeths Medical Center of Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST ELIZABETH S MEDICAL CT OF B, St Elizabeths Medical Center of Boston Inc filed Critical ST ELIZABETH S MEDICAL CT OF B
Publication of AU2001296521A1 publication Critical patent/AU2001296521A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001296521A 2000-10-02 2001-10-02 Use of lymphangiogenic agents to treat lymphatic disorders Abandoned AU2001296521A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23717100P 2000-10-02 2000-10-02
US60/237,171 2000-10-02
PCT/US2001/030904 WO2002029087A2 (en) 2000-10-02 2001-10-02 Use of lymphangiogenic agents to treat lymphatic disorders

Publications (1)

Publication Number Publication Date
AU2001296521A1 true AU2001296521A1 (en) 2002-04-15

Family

ID=22892613

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296521A Abandoned AU2001296521A1 (en) 2000-10-02 2001-10-02 Use of lymphangiogenic agents to treat lymphatic disorders

Country Status (3)

Country Link
US (1) US20020151489A1 (en)
AU (1) AU2001296521A1 (en)
WO (1) WO2002029087A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2002011769A1 (en) * 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
AU2002248372B8 (en) * 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
EP1385864B1 (en) * 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 antibodies
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
JP2005500045A (en) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ Lymphatic endothelial cell material and method
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
DE10242663A1 (en) * 2002-09-13 2004-03-25 Forschungszentrum Karlsruhe Gmbh Identifying inhibitors of metastasis or lymphangiogenesis, useful for treating cancer, by in vivo testing for inhibiting the activation of vascular endothelial growth factor receptor-3
WO2004070018A2 (en) * 2003-02-04 2004-08-19 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells
WO2005011722A2 (en) * 2003-06-12 2005-02-10 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
KR20140068234A (en) 2005-03-31 2014-06-05 더 제너럴 하스피탈 코포레이션 Monitoring and modulating hgf/hgfr activity
US20080051644A1 (en) * 2006-02-17 2008-02-28 Raymond Tabibiazar Lymphedema associated genes and model
WO2012016070A2 (en) 2010-07-30 2012-02-02 The Board Of Trustees Of The Leland Stanford Junior University Lymphedema associated genes and model
KR101336386B1 (en) * 2011-06-17 2013-12-04 전북대학교병원 Revellent lymph blood vessel
US20140212860A1 (en) * 2013-01-31 2014-07-31 Novadaq Technologies Inc. Virtual-reality simulator to provide training for sentinel lymph node surgery using image data and database data
MX368730B (en) 2013-02-18 2019-10-14 Vegenics Pty Ltd Ligand binding molecules and uses thereof.
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
WO2019094938A2 (en) 2017-11-13 2019-05-16 The University Of Chicago Methods and compositions for the treatment of wounds
JP2022512844A (en) * 2018-11-16 2022-02-07 イエール ユニバーシティ Manipulation of the meningeal lymphatic system for the treatment of brain and CNS tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
NZ505011A (en) * 1997-12-24 2004-12-24 Ludwig Inst Cancer Res Expression vectors and cell lines expressing VEGF-D and method of treating melanomas

Also Published As

Publication number Publication date
US20020151489A1 (en) 2002-10-17
WO2002029087A3 (en) 2003-11-27
WO2002029087A2 (en) 2002-04-11
WO2002029087A9 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AU2001296521A1 (en) Use of lymphangiogenic agents to treat lymphatic disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
AU2002305756A8 (en) Use of nf-kappa-b inhibitors to treat dry eye disorders
AU2001294515A1 (en) Use of stat-6 inhibitors as therapeutic agents
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
HUP0500001A3 (en) Use of pramipexole to treat amyotrophic lateral sclerosis
IL160928A0 (en) Use of histamine to treat liver disease
IL147891A0 (en) Topical use of anti-muscarnic agents
MXPA03007653A (en) Use of lp82 to treat hematopoietic disorders.
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
AU2001287534A1 (en) Use of flupirtine to treat tinnitus
AU2002340465A1 (en) Cyclo(prolyl-glycine) and methods of use to treat neural disorders
IL150479A0 (en) Treatment of psoriasis
HRP20030384A2 (en) Treatment of anxiety disorders
GB2360453B (en) Treatment of skin conditions
AU2002236116A1 (en) Method to treat soapy wastewater
AU4838301A (en) Treatment of disorders relating to the serotonergic system
GB0003201D0 (en) Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
AU2001272902A1 (en) Treating musculoskeletal disorders using lp85 and analogs thereof
SG90719A1 (en) Novel therapeutic and prophylactic agents and methods of using same
TW423322U (en) Improved structure of massage pad
HUP0302882A3 (en) Improved specificity in treatment of diseases
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
HUP0204040A3 (en) Novel therapeutic use of enoxaparin